Open AccessMetabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non‐small cell lung cancer
Author(s) -
Fernández Lara Paula,
Merino María,
Colmenarejo Gonzalo,
MorenoRubio Juan,
SánchezMartínez Ruth,
QuijadaFreire Adriana,
Gómez de Cedrón Marta,
Reglero Guillermo,
Casado Enrique,
Sereno María,
Ramírez de Molina Ana
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12816
Subject(s) - lipid metabolism , lung cancer , simvastatin , biomarker , cancer research , cancer , statin , biology , pharmacology , medicine , oncology , biochemistry
Overexpression of the enzyme ACSL3 is an unfavorable prognostic marker in non‐small cell lung cancer (NSCLC). Moreover, overexpression of ACSL3 increases cell proliferation, migration, and invasion, altering the metabolic properties of cancer cells. Administration of statins causes antiproliferative effects and, importantly, patients with high expression levels of ACSL3 following statin treatment display better prognosis than those not treated with statins.